C. Saura Manich

机构：Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

发表论文 81 篇 · 总被引 1036 次 · h-index 9

代表论文

• Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. (2025 · Journal of Clinical Oncology · 被引 31)
• Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial. (2025 · Journal of Clinical Oncology · 被引 7)
• Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA -mutant HR+HER2- advanced breast cancer: ReDiscover trial. (2025 · Journal of Clinical Oncology · 被引 6)
• LBA12 5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial (2025 · Annals of Oncology · 被引 4)
• LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest (2025 · Annals of Oncology · 被引 4)
• Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial. (2025 · Journal of Clinical Oncology · 被引 3)